NERV · XBRL financial data

Minerva Neurosciences financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (NERV's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022†Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	41,176	—	—	—	—	—
Revenue from contracts with customers	0	0	0	0	0	—
Research and development	22,039	32,039	14,649	12,705	11,899	5,759
General and administrative	17,289	13,327	10,582	10,414	9,950	9,343
Total operating expenses	39,329	45,366	25,231	23,120	21,848	15,103
Operating income (loss)	1,847	(45,366)	(25,231)	(23,120)	(21,848)	(15,103)
Interest income	161	17	557	1,437	1,272	948
Income tax expense (benefit)	—	(1,803)	—	—	—	—
Net income (loss)	1,941	(49,906)	(32,109)	(30,005)	1,439	(293,423)
Earnings per share, basic USD per share	0.05	(1.17)	(6.01)	(4.61)	0.19	(34.67)
Earnings per share, diluted USD per share	0.05	(1.17)	(6.01)	(4.61)	0.19	(34.67)
Weighted average shares, basic thousands of shares	40,824	42,722	5,340	6,506	7,569	8,464
Weighted average shares, diluted thousands of shares	40,917	42,722	5,340	6,506	7,574	8,464

† Share count changed about 1/8 in the period ending 2022-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (NERV's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022†Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	25,357	60,755	36,094	40,913	21,362	82,302
Total current assets	27,440	62,201	40,159	42,002	22,269	83,099
Property and equipment, net	—	—	16	11	5	0
Right-of-use asset	102	—	—	—	—	—
Goodwill	14,869	14,869	14,869	14,869	14,869	14,869
Total assets	57,626	77,122	55,087	56,900	37,144	97,969
Accounts payable	996	1,853	970	1,805	1,608	640
Total current liabilities	3,160	2,819	1,378	3,340	2,837	2,290
Total liabilities	4,964	69,146	75,111	85,357	62,837	233,755
Accumulated deficit	(284,795)	(334,701)	(366,810)	(396,815)	(395,377)	(688,800)
Total stockholders' equity	52,663	7,976	(20,024)	(28,457)	(25,693)	(140,748)
Total liabilities and equity	57,626	77,122	55,087	56,900	37,144	97,969
Common shares outstanding (cover page) thousands of shares	42,722	42,722	5,340	6,993	6,993	43,274

† Share count changed about 1/8 in the period ending 2022-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (NERV's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022†Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	1,941	(49,906)	(32,109)	(30,005)	1,439	(293,423)
Stock-based compensation	9,704	5,219	4,109	1,968	1,326	1,327
Depreciation and amortization	16	—	—	—	—	—
Net cash from operating activities	(33,822)	(24,602)	(24,645)	(14,785)	(19,551)	(13,511)
Purchases of property and equipment	—	—	16	—	—	—
Net cash from investing activities	24,528	—	(16)	0	0	0
Net cash from financing activities	13,238	60,000	(0)	19,604	—	74,451
Net change in cash	3,944	35,398	(24,661)	4,819	(19,551)	60,940

† Share count changed about 1/8 in the period ending 2022-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.
A cell reading “year only” links to a 10-K that gives only the full year: without all three earlier quarters there is no fourth quarter to work out, and the year total is never shown as a quarter.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Minerva Neurosciences	24,652	not reported	(13,345)*	47.7M	5.6 quarters	Q2 FY26 10-QJun 30, 2026
CV Sciences	266	2,985	20*	225.8M	—	Q2 FY26 10-QJun 30, 2026
Neuphoria Therapeutics	19,866	year only	1,214*	5.4M	—	Q4 FY26 10-KJun 30, 2026
Sunshine Biopharma	13,748	9,264	(918)*	3.9M	15.0 quarters	Q2 FY26 10-QJun 30, 2026
Zeo ScientifiX	2,265	not reported	not reported	7.8M	—	Q4 FY26 10-KTJun 30, 2026
Bolt Biotherapeutics	12,860	5	(6,540)*	1.9M	2.7 quarters	Q2 FY26 10-QJun 30, 2026
Protagenic Therapeutics, Inc.\new	566	not reported	(944)	1.8M	0.6 quarters	Q1 FY26 10-QJun 30, 2026
Intensity Therapeutics	9,529	not reported	(2,340)*	3.3M	4.1 quarters	Q2 FY26 10-QJun 30, 2026
Biomerica	2,733	1,265	(802)	4.6M	3.4 quarters	Q1 FY27 10-QAug 31, 2026

Not investment advice. Not affiliated with the U.S. SEC.